NMN vs. NR: Which NAD+ Booster — and the FDA Situation, Explained
Educational summary — not medical advice. Neither NMN nor NR is a proven anti-aging or lifespan-extending treatment in humans; no human lifespan data exists for either compound. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
The honest answer
NMN's regulatory status is resolved, but it took three years: the FDA excluded NMN from the legal dietary-supplement definition in November 2022, Amazon pulled every NMN listing by March 2023, and in September 2025 the FDA reversed course and confirmed NMN is NOT excluded — Amazon relisted within weeks. NR never went through that: it has a cleaner, uninterrupted regulatory history. Mechanistically, NR has a more direct cell-uptake pathway; NMN generally must be broken down to NR outside the cell first. Neither compound has proven anti-aging or lifespan benefits in humans.
The FDA story, start to finish (resolved as of today)
This is the single most-asked question about NMN, and the honest answer is that it's settled history now, not a live risk — but the timeline is worth knowing because the volatility itself is a reason to buy carefully.
The FDA excluded NMN from the legal definition of a dietary supplement, citing the agency's drug-preclusion clause: NMN had been authorized for investigation as a new drug (an Investigational New Drug application, reportedly tied to the pharmaceutical company MetroBiotech) before it was marketed as a supplement ingredient — a technical exclusion trigger, not a safety finding against NMN itself.
Amazon pulled NMN listings from its marketplace in response to the FDA's position, effectively removing NMN from the largest US retail channel.
The Natural Products Association (NPA), an industry trade group, filed a citizen petition asking the FDA to reconsider, and when that didn't resolve the issue, filed a lawsuit against the FDA in August 2024.
The FDA reversed its position in a 26-page letter, confirming NMN is not excluded from the dietary-supplement definition, based on evidence that NMN had been marketed as a supplement before the relevant 2016 cutoff date the drug-preclusion clause depends on.
Amazon relisted NMN products within weeks of the FDA's reversal, restoring the category to the marketplace.
State this as what it is: history that has already resolved, as of today. It is not an open regulatory question. But the whiplash — excluded, delisted, and reinstated within roughly three years — is exactly why the best-NMN page ranks third-party-testing disclosure ahead of price: a category whose retail catalog can be wiped and rebuilt that fast is one where brand-name trust alone is a weaker signal than usual.
The mechanism: how each one actually gets into a cell
NMN and NR are both precursors the body converts into NAD+, but they take measurably different routes to get there. NR has a comparatively clear, well-characterized path: it enters cells directly through equilibrative nucleoside transporters (ENTs) and is phosphorylated to NMN once inside the cell, where it continues on to NAD+. NMN's path is murkier — in most experimental models, extracellular NMN appears to require dephosphorylation to NR before it can cross the cell membrane, meaning it may effectively need to become NR-like to get in, a more roundabout route than NR takes directly. This is a real mechanistic distinction backed by cell-biology research, not a marketing claim — but it's worth being precise about what it does and doesn't tell you: a cleaner uptake pathway in cell models is not the same as a proven better clinical outcome in humans, and neither compound's human pharmacokinetics are fully mapped.
The regulatory contrast: NR never had this problem
While NMN was excluded from the supplement definition for roughly three years, NR never lost its GRAS (Generally Recognized As Safe) or New Dietary Ingredient standing — it has an uninterrupted regulatory history that NMN, until September 2025, did not. That's a genuinely useful piece of information for anyone weighing the two: NR's paper trail with US regulators has been cleaner and more stable, independent of anything about its biological effectiveness.
The evidence contrast: press coverage vs. a published rebuttal
NMN's human evidence includes the trial that got the most mainstream press — Yoshino 2021, published in Science, which found NMN improved insulin sensitivity in a small group of prediabetic postmenopausal women. It's also NIH-funded, academic, non-industry work, which is a real point in its favor. But it's also the trial with a published methodological rebuttal: the NMN group started with significantly lower baseline liver fat than the placebo group (6.3% vs 14.8%, p=0.003) — a randomization imbalance directly relevant to an insulin-sensitivity outcome, disclosed in a formal Comment on the original paper. NR's human trial volume is smaller and more modest overall, without a single trial that drew comparable press attention or a comparable published rebuttal. Neither compound has a large, independently replicated trial proving a disease-outcome or longevity benefit in humans.
The one-line takeaway NR has the cleaner regulatory paper trail — it never lost its legal standing the way NMN did for nearly three years. NMN has the trial that got the press (Yoshino 2021) and also the trial that got a published rebuttal. Neither is a proven longevity drug in humans, and no human lifespan data exists for either compound. Choosing between them is a mechanism-and-regulatory-history question, not a "which one is proven to work better" question — because neither is proven to that standard yet.
Frequently asked questions
Is NMN legal to sell as a supplement right now?
Yes. Excluded Nov 2022, delisted from Amazon by March 2023, FDA reversed course Sept 2025 confirming NMN is not excluded, Amazon relisted within weeks. Resolved as of today.
What is the difference between NMN and NR?
NR enters cells directly via ENTs and is phosphorylated to NMN inside the cell. NMN generally must be dephosphorylated to NR outside the cell first — a more roundabout uptake route.
Does NR have better regulatory standing than NMN?
Yes. NR never lost GRAS/NDI standing; NMN was excluded from the supplement definition for roughly three years before the FDA reversed course in Sept 2025.
Which one actually works better?
Neither is proven as a longevity treatment. NMN has the most-cited positive trial (Yoshino 2021) and its published rebuttal; NR has a cleaner regulatory history and a smaller, more modest trial volume.
Related
- NMN: what it is & who it's for
- NMN dosage guide — 250-1200 mg range and the safety ceiling
- Best NMN — ranked by purity/testing disclosure, then cost per mg
- NMN for walking speed & muscle function
- Boron — the site's other regulatory-honesty structural twin (boric-acid/borax confusion)
Sources
- Yoshino M, Imai S, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021. PMID: 33888596
- U.S. Food and Drug Administration correspondence regarding NMN's dietary-supplement status, November 2022 exclusion and September 2025 reversal letter (26 pages, citing pre-2016 marketing evidence).
- Natural Products Association citizen petition (2023) and lawsuit against FDA (filed August 2024) regarding NMN's regulatory status.
- Full NMN product dataset: /nmn/cost-by-brand.json (CC BY 4.0).